|Accession Number||DB01125 (APRD00799)|
Anisindione is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K-mediated gamma-carboxylation of precursor proteins.
|External IDs||Not Available|
|Product Ingredients||Not Available|
|Approved Prescription Products||Not Available|
|Approved Generic Prescription Products||Not Available|
|Approved Over the Counter Products||Not Available|
|Unapproved/Other Products||Not Available|
|Brand mixtures||Not Available|
|Weight||Average: 252.2647 |
For the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion.
|Structured Indications||Not Available|
Anisindione is a synthetic anticoagulant and an indanedione derivative. It is prescribed only if you cannot take coumarin-type anticoagulants such as coumadin as anisindione is a powerful drug with serious potential side effects. Anticoagulants decrease the clotting ability of the blood and therefore help to prevent harmful clots from forming in the blood vessels. These medicines are sometimes called blood thinners, although they do not actually thin the blood. They also will not dissolve clots that already have formed, but they may prevent the clots from becoming larger and causing more serious problems.
|Mechanism of action|
Like phenindione, to which it is related chemically, anisindione exercises its therapeutic action by reducing the prothrombin activity of the blood. Anisindione prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K–mediated gamma-carboxylation of precursor proteins. Anisindione has no direct thrombolytic effect and does not reverse ischemic tissue damage, although it may limit extension of existing thrombi and prevent secondary thromboembolic complications.
Accumulation does not occur with repeated dosing.
|Volume of distribution||Not Available|
|Route of elimination||Not Available|
An overdose is likely to cause abnormal bleeding, for which the symptoms include: bleeding from gums or nose, blood in urine or stools, excessive bleeding from minor cuts, patches of discoloration or bruises on the skin.
|Pharmacogenomic Effects/ADRs||Not Available|
|Drug Interactions||Not Available|
|Food Interactions||Not Available|
Sperber, N.; US. Patent 2,899,358; August 11, 1959; assigned to Schering Corporation
|ATC Codes||Not Available|
|AHFS Codes||Not Available|
|PDB Entries||Not Available|
|FDA label||Not Available|
|Clinical Trials||Not Available|
|Dosage forms||Not Available|
|Predicted ADMET features|
|Mass Spec (NIST)||Not Available|
|Description||This compound belongs to the class of chemical entities known as indanediones. These are compounds containing an indane ring bearing two ketone groups.|
|Super Class||Organic compounds|
|Alternative Parents||Phenoxy compounds / Methoxybenzenes / Aryl alkyl ketones / Anisoles / Beta-diketones / Alkyl aryl ethers / Organic oxides / Hydrocarbon derivatives|
|Substituents||Indanedione / Phenoxy compound / Anisole / Methoxybenzene / Aryl alkyl ketone / Aryl ketone / Phenol ether / Alkyl aryl ether / 1,3-diketone / Monocyclic benzene moiety|
|Molecular Framework||Aromatic homopolycyclic compounds|
|External Descriptors||aromatic ketone, beta-diketone (CHEBI:133809 )|
- Pharmacological action
- General Function:
- Gamma-glutamyl carboxylase activity
- Specific Function:
- Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide.
- Gene Name:
- Uniprot ID:
- Molecular Weight:
- 87560.065 Da
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
- Source [Link]